高级搜索

单发2cm以下微血管侵犯肝癌患者的预后生存分析

张麒, 张文, 查勇, 甘平

张麒, 张文, 查勇, 甘平. 单发2cm以下微血管侵犯肝癌患者的预后生存分析[J]. 肿瘤防治研究, 2015, 42(04): 356-358. DOI: 10.3971/j.issn.1000-8578.2015.04.008
引用本文: 张麒, 张文, 查勇, 甘平. 单发2cm以下微血管侵犯肝癌患者的预后生存分析[J]. 肿瘤防治研究, 2015, 42(04): 356-358. DOI: 10.3971/j.issn.1000-8578.2015.04.008
ZHANG Qi, ZHANG Wen, ZHA Yong, GAN Ping. Long-term Survival of Single Hepatocellular Carcinoma ≤2cm with Microvascular Invasion[J]. Cancer Research on Prevention and Treatment, 2015, 42(04): 356-358. DOI: 10.3971/j.issn.1000-8578.2015.04.008
Citation: ZHANG Qi, ZHANG Wen, ZHA Yong, GAN Ping. Long-term Survival of Single Hepatocellular Carcinoma ≤2cm with Microvascular Invasion[J]. Cancer Research on Prevention and Treatment, 2015, 42(04): 356-358. DOI: 10.3971/j.issn.1000-8578.2015.04.008

单发2cm以下微血管侵犯肝癌患者的预后生存分析

基金项目: 云南省应用基础研究计划(2011FB064)
详细信息
    作者简介:

    张麒(1978-),男,本科,主治医师,主要从事消化道肿瘤的防治研究

    通讯作者:

    甘平,E-mail: ganping9@163.com

  • 中图分类号: R735.7

Long-term Survival of Single Hepatocellular Carcinoma ≤2cm with Microvascular Invasion

  • 摘要: 目的 2 cm以下的单发肝癌有着良好的术后生存。而微血管侵犯被认为是影响肝癌预后的独立危险因素,其对单发小肝癌(≤2 cm)的影响尚不清楚。本研究的目的在于研究微血管侵犯对于2 cm以下单发肝癌预后的影响。方法 回顾性分析云南省肿瘤医院2001年1月至2008年12月间住院的62例2 cm以下单发肝癌患者的临床及术后病理资料,探讨微血管侵犯对预后的影响。结果 62例2 cm以下单发肝癌患者中,16例有微血管侵犯、46例无微血管侵犯。16例有微血管侵犯的患者,其术后5年生存率为81.3%,而无微血管侵犯患者的术后5年生存率为93.5%,两者之间差异无统计学意义(P=0.496)。结论 2 cm以下的单发肝癌有着良好的预后,微血管侵犯不影响2 cm以下单发肝癌的长期生存;为了确认微血管侵犯是否不影响2 cm以下单发肝癌的长期生存,仍需要多中心大样本的数据进行进一步验证。

     

    Abstract: Objective Excellent long-term outcomes have been reported recently for patients with single hepatocellular carcinoma(HCC) ≤2cm. However, how microvascular invasion(MVI), as an independent risk factor for HCC, affects small single HCC remains unclear. The purpose of this paper is to determine the impact of MVI on the prognosis of single HCC ≤2cm. Methods We retrospectively reviewed clinicopathological data of 62 patients with HCC ≤ 2cm, hospitalized from January 2001 to December 2008 in Yunnan Provincial Cancer Hospital. Results Among 62 patients, the 5-year overall survival(OS) rate of 16 patients with MVI was 81.3%, while that of 46 patients without MVI was 93.5% (P=0.496). Conclusion Patients with single HCC ≤2cm have excellent prognosis, and MVI has no influence on the 5-years overall survival rate; while it still needs further validation by multi-centers' and large sample size investigation to confirm if MVI affects the long-term survival or not.

     

  • [1] Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010, 17(6): 1471-4.
    [2] Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2003, 362(9399): 1907-17.
    [3] Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan[J].Hepatology, 2000, 32(6): 1224-9.
    [4] Yamashita YI, Tsuijita E, Takeishi K, et al. Predictors for microinvasion of small hepatocellular carcinoma≤2 cm[J]. Ann Surg Oncol, 2012, 19(6): 2027-34.
    [5] Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer≤2 cm: results from two Western centers[J]. Hepatology, 20 13, 57(4): 1426-35.
    [6] Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?[J]. Hepatology, 2008, 47(1): 82-9.
    [7] Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma[J]. Ann Surg, 20 06, 243(3): 321-8.
    [8] Zhou Y, Zhao Y, Li B, et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma[J]. BMC Gastroenterol, 2010, 10: 78.
    [9] Makuuchi M, Kokudo N, Arii S, et al. Development of evidencebased clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan[J]. Hepatol Res, 2008, 38(1): 37 -51.
    [10] Chinese Societies of Liver Cancer and Clinical Oncology, Chinese Anti-Cancer Association, Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Experts consensus on local ablation therapy for liver cancer[J]. Zhong Liu, 20 11, 31(5): 385-8. [中国抗癌协会肝癌专业委员会, 中国抗癌 协会临床肿瘤学协作专业委员会, 中华医学会肝病学分会肝癌 学组.肝癌局部消融治疗规范的专家共识[J]. 肿瘤, 2011, 31(5): 38 5-8.]
    [11] Huang ZQ. Radiofrequency ablation for hepatocellular carcinoma: surgeon’s views[J]. Jie Fang Jun Yi Xue Za Zhi, 2013, 38(5): 33 9-41. [黄志强. 肝细胞癌的射频消融治疗:外科医生的观点 [J] 解放军医学杂志, 2013, 38(5): 339-41.]
    [12] Lv WP, Zhou KL, Li J. et al. Predictors and prognosis of patients with advanced stage small hepatocellular carcinoma after hepatectomy[J]. Jie Fang Jun Yi Xue Za Zhi, 2013, 38(1): 44-7.[ 吕文平, 周开伦, 李杰, 等. 晚期小肝癌的临床预测因素及肝切 除术预后研究[J].解放军医学杂志, 2013, 38(1): 44-7.]
计量
  • 文章访问数:  2437
  • HTML全文浏览量:  316
  • PDF下载量:  894
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-03-22
  • 修回日期:  2014-05-22
  • 刊出日期:  2015-04-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭